Lupin Ltd’s Mixed Week: -0.23% Price Change Amidst Rising Derivatives Activity

4 hours ago
share
Share Via
Lupin Ltd experienced a modest decline of 0.23% over the week ending 2 January 2026, closing at Rs.2,108.00 against a backdrop of mixed technical momentum and a notable surge in derivatives market activity. While the broader Sensex advanced 1.35% during the same period, Lupin’s price action reflected investor caution amid shifting momentum indicators and increased open interest, signalling a complex interplay of short-term volatility and medium-term optimism.




Key Events This Week


29 Dec 2025: Significant open interest surge amid mixed price action (Rs.2,079.50)


30 Dec 2025: Technical momentum shifts with mixed market signals (Rs.2,081.00)


31 Dec 2025: Price rebounds with 1.49% gain (Rs.2,112.00)


1 Jan 2026: Slight pullback amid consolidation (Rs.2,103.30)


2 Jan 2026: Week closes with mild recovery (Rs.2,108.00)





Week Open
Rs.2,112.95

Week Close
Rs.2,108.00
-0.23%

Week High
Rs.2,112.00

vs Sensex
-1.58%



29 December 2025: Surge in Open Interest Amid Price Decline


On 29 December, Lupin Ltd’s stock price declined by 1.58% to close at Rs.2,079.50, underperforming the Sensex which fell 0.41% that day. Despite the price drop, the derivatives market showed heightened activity with open interest rising sharply by 12.54%, from 31,490 to 35,440 contracts. Futures volume was robust at 17,362 contracts, and the combined futures and options notional value reached approximately ₹8,23,15 lakhs, dominated by options at ₹7,39,645 lakhs.


This divergence between price weakness and rising open interest suggests active repositioning by market participants, possibly reflecting a mix of speculative short-term bearish bets and strategic accumulation by institutional investors. The stock traded below its short-term moving averages but remained above longer-term averages, indicating some near-term selling pressure amid a generally positive medium-term trend.


Investor participation was notable, with delivery volumes surging by over 213% compared to the five-day average, signalling increased conviction among longer-term holders despite the price dip.




Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.



  • - Strong fundamental track record

  • - Consistent growth trajectory

  • - Reliable price strength


Count on This Pick →




30 December 2025: Mixed Technical Momentum Amid Consolidation


On 30 December, Lupin’s share price marginally increased by 0.07% to Rs.2,081.00, while the Sensex edged down 0.01%. Technical indicators presented a nuanced picture: the weekly MACD remained bullish, supporting short-term momentum, but the monthly MACD turned mildly bearish, signalling weakening longer-term momentum. The Relative Strength Index (RSI) hovered in a neutral zone, indicating no extreme momentum bias.


The Know Sure Thing (KST) indicator echoed this mixed sentiment, bullish on the weekly timeframe but mildly bearish monthly. Daily moving averages continued to support a bullish stance, with the stock trading above key averages, and Bollinger Bands suggested contained volatility within an upward channel.


Volume analysis via On-Balance Volume (OBV) showed no clear trend confirmation, implying that price movements lacked strong volume support. Dow Theory assessments aligned with a mildly bullish outlook, indicating gradual accumulation rather than distribution.



31 December 2025 to 2 January 2026: Price Recovery and Consolidation


On 31 December, Lupin rebounded strongly, gaining 1.49% to close at Rs.2,112.00, outperforming the Sensex’s 0.83% gain. This recovery was followed by a slight pullback on 1 January, with the stock declining 0.41% to Rs.2,103.30 amid low volume, signalling consolidation. On 2 January, the stock edged up 0.22% to Rs.2,108.00, closing the week near its opening level but below the week’s high.


Throughout these sessions, the stock remained above key long-term moving averages, supporting the medium-term bullish case despite short-term volatility. The Sensex outperformed Lupin over the week, rising 1.35% compared to Lupin’s 0.23% decline, reflecting sector-specific pressures and mixed investor sentiment.




Want to dive deeper on Lupin Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!



  • - Real-time research report

  • - Complete fundamental analysis

  • - Peer comparison included


Read the Full Verdict →




Daily Price Comparison: Lupin Ltd vs Sensex


















































Date Stock Price Day Change Sensex Day Change
2025-12-29 Rs.2,079.50 -1.58% 37,140.23 -0.41%
2025-12-30 Rs.2,081.00 +0.07% 37,135.83 -0.01%
2025-12-31 Rs.2,112.00 +1.49% 37,443.41 +0.83%
2026-01-01 Rs.2,103.30 -0.41% 37,497.10 +0.14%
2026-01-02 Rs.2,108.00 +0.22% 37,799.57 +0.81%



Key Takeaways


Positive Signals: Lupin’s derivatives market activity surged notably, with open interest increasing by 12.54%, indicating strong investor engagement and potential for significant price moves. The stock remains above key long-term moving averages, supporting a medium-term bullish outlook. The Mojo Score upgrade to 71.0 with a Buy grade reflects improved fundamentals and analyst confidence.


Cautionary Signals: The stock underperformed the Sensex by 1.58% on the opening day of the week and closed the week down 0.23%, while the Sensex gained 1.35%. Mixed technical momentum, with weekly indicators bullish but monthly indicators mildly bearish, suggests potential volatility and the need for careful monitoring. Lack of volume confirmation on price moves adds to uncertainty in the short term.



Conclusion


Lupin Ltd’s week was characterised by a complex interplay of rising derivatives activity and mixed technical signals, resulting in a slight price decline despite broader market gains. The surge in open interest and delivery volumes points to heightened investor interest and possible repositioning ahead of future catalysts. While short-term momentum indicators show some fragility, the stock’s position above long-term moving averages and an upgraded Mojo Grade support a cautiously optimistic medium-term outlook. Investors should remain attentive to evolving technical trends and market developments to navigate potential volatility in this key pharmaceutical stock.






{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News